Business
Caribou Biosciences, Inc.: If we fail to obtain additional financing, we will be unable to complete the development and commercialization of our vispa-cel and/or CB-011 product candidates.
Revenue increased 11.7% to $11.2M, while Net income increased 0.7% to ($148.1M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $11.2MWatch
- Profitability — Net income ($148.1M)Watch
- Cash generation — Free cash flow ($112.4M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 0 buys; 5 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Caribou Biosciences, Inc. reports it. History and quarterly detail are in the app.
- Reportable$11.2M
Leadership changes
From Caribou Biosciences, Inc.'s own filings, the day they're filed.
- Syed Rizvi · Chief Medical Officer · departureeff. 2023-12-31
- Syed Rizvi · Chief Medical Officer · departureeff. 2023-12-31
- Ryan Fischesser · President · appointment
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Caribou Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.